Pharmaceutical Technology
SEPTEMBER 9, 2024
The microbiome, which consists of a vast array of microorganisms inhabiting the human body, has gained considerable attention for its role in health and disease.
AuroBlog - Aurous Healthcare Clinical Trials blog
SEPTEMBER 9, 2024
(Derek Berwin/Getty Images) TThe human papillomavirus (HPV) is responsible for the vast majority of cervical cancer cases, but this isn’t a sexually transmitted infection that just one half of the population needs to worry about.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
SEPTEMBER 9, 2024
CC-115 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Solid Tumor.
AuroBlog - Aurous Healthcare Clinical Trials blog
SEPTEMBER 9, 2024
The convergence of gene therapies and clinical research is pushing the boundaries of what’s possible in ophthalmic care, offering hope for more effective treatments and potential cures for a range of vision-threatening conditions.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmaceutical Technology
SEPTEMBER 9, 2024
Ifetroban is under clinical development by Cumberland Pharmaceuticals and currently in Phase II for Asthma.
Bio Pharma Dive
SEPTEMBER 9, 2024
A once-daily pill the biotech is developing helped some people with obesity lose more than 5% of their weight in a month, spurring a stock bump and plans to bring the drug into further testing.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Bio Pharma Dive
SEPTEMBER 9, 2024
Results from a small study suggest Relay's drug could avoid some of the toxicity associated with existing PI3Ka inhibitors like Novartis' Piqray.
Pharmaceutical Technology
SEPTEMBER 9, 2024
Venetoclax is under clinical development by AbbVie and currently in Phase III for Mantle Cell Lymphoma.
Bio Pharma Dive
SEPTEMBER 9, 2024
The startup believes T cell engagers, rather than cell therapies, will prove the “right horse to bet on” in the race to develop new inflammatory disease treatments, its CEO said.
Pharmaceutical Technology
SEPTEMBER 9, 2024
Envafolimab is under clinical development by Alphamab Oncology and currently in Phase II for Papillary Thyroid Cancer.
Bio Pharma Dive
SEPTEMBER 9, 2024
The escalating global challenge of Alzheimer's Disease (AD) demands new approaches to detection, diagnosis and treatment.
Pharmaceutical Technology
SEPTEMBER 9, 2024
Alpha-1 proteinase inhibitor (human) second generation is under clinical development by Kamada Pharmaceuticals and currently in Phase II for Alpha-1…
Pharma Times
SEPTEMBER 9, 2024
Research suggests that LLMs could be used to support trainee doctors, nurses and GPs
Pharmaceutical Technology
SEPTEMBER 9, 2024
Immunovant is ramping up Graves’ disease activity with more batoclimab data and an IMVT-1402 IND clearance.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
pharmaphorum
SEPTEMBER 9, 2024
Summit Therapeutics and Akeso's ivonescimab tops Merck's Keytruda in head-to-head phase 3 trial in first-line NSCLC, reported at WCLC.
Pharmaceutical Technology
SEPTEMBER 9, 2024
PolTREG plans to start a pivotal Phase II/III trial for its Treg cell therapy after it induced clinical remission in type 1 diabetics.
Pharmaceutical Commerce
SEPTEMBER 9, 2024
In the second part of her interview with Pharma Commerce Editor Nicholas Saraceno, Meghan Mullooly, Archbow Consulting’s Vice President, offers advice to pharma manufacturers for successfully applying digital solutions to their patient support programs.
Pharmaceutical Technology
SEPTEMBER 9, 2024
Epsilogen has raised £12.5m in a Series B expansion financing round to progress the development of IgE antibodies for cancer.
pharmaphorum
SEPTEMBER 9, 2024
Discover how Chiesi is leading the way in pharmaceutical sustainability by partnering with EcoVadis and implementing innovative practices. Learn how they are making a positive impact on the environment and society.
Pharmaceutical Technology
SEPTEMBER 9, 2024
Formosa Pharmaceuticals has announced the first shipment of clobetasol propionate ophthalmic suspension 0.05% (APP13007) to the US.
XTalks
SEPTEMBER 9, 2024
The medical device industry continues to thrive in 2024, with advancements in technology shaping the future of healthcare. From cutting-edge surgical robotics to innovative diagnostic tools, the top publicly traded medical device companies are delivering solutions that improve patient care and expand the capabilities of healthcare professionals. Abbott, for instance, leads the industry with breakthroughs in diabetes care and diagnostics, while Stryker’s innovations in orthopedic devices and robo
Pharmaceutical Technology
SEPTEMBER 9, 2024
OrsoBio has secured $67m in a Series B financing round to expedite the development of its mitochondrial protonophore portfolio.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
pharmaphorum
SEPTEMBER 9, 2024
AI biomarker could help identify lung cancer patients most likely to benefit from AstraZeneca and Daiichi Sankyo's TROP2 drug Dato-DXd.
Pharmaceutical Technology
SEPTEMBER 9, 2024
Sun Pharma and Moebius Medical have received FDA fast track designation (FTD) for MM-II for osteoarthritis knee pain.
Pharmaceutical Commerce
SEPTEMBER 9, 2024
The latest news for pharma industry insiders.
XTalks
SEPTEMBER 9, 2024
Diversity, equity and inclusion (DEI) have become important elements in the landscape of clinical research. It is important for the principles of DEI to be understood for their goals, intended outcomes and applications; otherwise, they may be regarded as mere buzzwords or just another box to tick on organizational mandates. DEI are critical components of building a thriving, fair, all-encompassing, respectful and innovative society.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Pharmaceutical Technology
SEPTEMBER 9, 2024
Sildenafil citrate is under clinical development by XOMA Royalty and currently in Phase II for Female Hypoactive Sexual Desire Disorder.
Fierce Pharma
SEPTEMBER 9, 2024
With the expiration of a contract to produce antibiotic medicines for Sandoz, GSK will shutter a 75-year-old manufacturing facility in its home country. The U.K. | With the expiration of a contract to produce antibiotic medicines for Sandoz, GSK will shutter a 75-year-old manufacturing facility in its home country.
Pharmaceutical Technology
SEPTEMBER 9, 2024
CMN-005 is under clinical development by CoImmune and currently in Phase II for Mantle Cell Lymphoma.
Fierce Pharma
SEPTEMBER 9, 2024
Three months on, Eli Lilly has closed the books on its search for a new chief financial officer. And as with its previous CFO, Anat Ashkenazi, the company didn’t have to look far. | Lilly on Monday revealed that it’s slotting 23-year company veteran Lucas Montarce into the finance chief role after the pharma’s previous CFO, Anat Ashkenazi, announced her departure in early June.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Expert insights. Personalized for you.
130 
Let's personalize your content